Which autoantibody panel is commonly used to screen for systemic autoimmune rheumatic diseases, and what pattern is often associated with SLE?

• A. RF panel; centromere pattern.
• B. ANA screen; dsDNA, Sm, SSA/SSB; homogeneous or speckled patterns with high titer often associated with SLE; dsDNA correlates with disease activity.
• C. ANA screen only; nucleolar pattern.
• D. ANCA with PR3/MPO; cytoplasmic pattern.

Answer: (B)

Starting with a broad screening approach, an ANA screen is used because it’s highly sensitive for detecting autoantibodies associated with systemic autoimmune rheumatic diseases. A positive ANA test signals that autoimmune activity is present and should be followed by more specific antibody testing, such as dsDNA, Sm, and SSA/SSB, to pinpoint the underlying condition.

In systemic lupus erythematosus (SLE) specifically, ANA patterns tend to be homogeneous or speckled, and these are usually seen with a high titer. Among the specific antibodies, anti-dsDNA is particularly linked to SLE and is notable for correlating with disease activity, including lupus nephritis—titers often rise with flares.

Other options point toward different diseases or patterns. A RF panel with a centromere pattern is more aligned with other rheumatic conditions or limited scleroderma, not the typical screening for SARDs. An ANA screen by itself with a nucleolar pattern is less characteristic for SLE. ANCA testing for PR3/MPO is associated with vasculitides, not the broad screening approach for systemic autoimmune diseases.

So the best choice uses the ANA screen with antibodies like dsDNA, Sm, and SSA/SSB, describes homogeneous or speckled patterns at high titer typical of SLE, and notes that dsDNA titer often mirrors disease activity.